Safety of long-term monthly cycles of methylprednisolone in combination with interferon β-1a IM in treatment-naive early relapsing-remitting multiple sclerosis patients in the MECOMBIN trial

被引：0
|
作者：
Ravnborg, M.
Sorensen, P. S.
Andersson, M.
Celius, E. Gulowsen
Jongen, P.
Batholome, E.
Elovaara, I.
Beer, K.
Sperling, B.
机构：
来源：
MULTIPLE SCLEROSIS | 2009年 / 15卷 / 09期
关键词：
D O I：
暂无
中图分类号：
R74 [神经病学与精神病学];
学科分类号：
摘要：
引用
收藏
页码：S243 / S243
页数：1
相关论文
共 50 条
  • [31] Long-term efficacy and safety of intramuscular interferon beta-1a: Randomized postmarketing trial of two dosing regimens in Japanese patients with relapsing-remitting multiple sclerosis
    Saida, Takahiko
    Kira, Jun-ichi
    Ueno, Yasuhiro
    Harada, Naozumi
    Hirakata, Toshiyuki
    MULTIPLE SCLEROSIS AND RELATED DISORDERS, 2016, 7 : 102 - 108
  • [32] Long-term adherence of patients with relapsing-remitting multiple sclerosis to subcutaneous self-injections of interferon β-1a using an electronic device: the RIVER study
    Lugaresi, Alessandra
    De Robertis, Francesca
    Clerico, Marinella
    Morra, Vincenzo Brescia
    Centonze, Diego
    Borghesan, Stefano
    Maniscalco, Giorgia Teresa
    EXPERT OPINION ON DRUG DELIVERY, 2016, 13 (07) : 931 - 935
  • [33] Simvastatin treatment in patients with relapsing-remitting multiple sclerosis receiving interferon beta 1a: a double-blind randomized controlled trial
    Togha, Mansoureh
    Karvigh, Sanaz Ahmadi
    Nabavi, Masoud
    Moghadam, Nahid Beladi
    Harirchian, Mohammad Hossein
    Sahraian, Mohammad Ali
    Enzevaei, Anahita
    Nourian, Alireza
    Ghanaati, Hossein
    Firouznia, Kavous
    Jannati, Ali
    Shekiba, Majid
    MULTIPLE SCLEROSIS JOURNAL, 2010, 16 (07) : 848 - 854
  • [34] Improvement in MRI outcomes across subgroups with alemtuzumab versus interferon beta-1a in treatment-naive relapsing-remitting multiple sclerosis
    Montalban, X.
    Arnold, D. L.
    Fisher, E.
    Margolin, D. H.
    Palmer, J.
    MULTIPLE SCLEROSIS JOURNAL, 2014, 20 : 83 - 84
  • [35] The long-term safety and tolerability of high-dose interferon β-1a in relapsing-remitting multiple sclerosis:: 4-year data from the PRISMS study
    Gold, R
    Rieckmann, P
    Chang, P
    Abdalla, J
    EUROPEAN JOURNAL OF NEUROLOGY, 2005, 12 (08) : 649 - 656
  • [36] Autologous T-Cell Immunotherapy (Tovaxin®) in Treatment-Naive Patients with Active Relapsing-Remitting Multiple Sclerosis
    Markowitz, Clyde
    Wynn, Daniel
    Fox, Edward
    Cohan, Stanley
    McGuire, Dawn
    NEUROLOGY, 2011, 76 (09) : A611 - A612
  • [37] The real life impact of early versus delayed treatment of interferon beta on long-term disability progression in relapsing-remitting multiple sclerosis
    Trojano, Maria
    Amato, Maria Pia
    Avolio, Carlo
    Bergamaschi, Roberto
    Cavalla, Paola
    Durelli, Luca
    Fuiani, Aurora
    Ghezzi, Angelo
    Lugaresi, Alessandra
    Lus, Giacomo
    Millefiorini, Enrico
    Paolicelli, Damiano
    Patti, Francesco
    Pellegrini, Fabio
    Imbaro, S. Maria
    Pozzilli, Carlo
    Rossi, Paolo
    Salemi, Giuseppe
    Vianello, Marica
    Livrea, Paolo
    Comi, Giancarlo
    NEUROLOGY, 2008, 70 (11) : A88 - A88
  • [38] Long-term follow-up of laquinimod in patients with relapsing-remitting multiple sclerosis
    Comi, G.
    Vollmer, T. L.
    Ashtamker, N.
    Sidi, Y.
    Ladkani, D.
    Gorfine, T.
    Sorensen, P. S.
    MULTIPLE SCLEROSIS JOURNAL, 2014, 20 : 39 - 39
  • [39] Long-term follow-up of laquinimod in patients with relapsing-remitting multiple sclerosis
    Comi, G.
    Vollmer, T. L.
    Lublin, F. D.
    Dadon, Y.
    Gorfine, T.
    Davis, M. D.
    Sorensen, P. S.
    Knappertz, V.
    MULTIPLE SCLEROSIS JOURNAL, 2015, 21 : 122 - 123
  • [40] The ACROSS study: Long-term efficacy of fingolimod in patients with relapsing-remitting multiple sclerosis
    Derfuss, T.
    Sastre-Garriga, J.
    Montalban, X.
    Rodegher, M.
    Wuerfel, J.
    Gaetano, L.
    Tomic, D.
    Azmon, A.
    Wolf, C.
    Kappos, L.
    MULTIPLE SCLEROSIS JOURNAL-EXPERIMENTAL TRANSLATIONAL AND CLINICAL, 2020, 6 (01)
12345